PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2472451-1 1989 FK506, a neutral macrolide with immunosuppressive properties, was shown to selectively and rapidly inhibit the accumulation of IL-2 mRNA, as well as the mRNAs of other early (E) phase T cell activation genes such as IL-3, IL-4, GM-CSF, TNF alpha, IFN-gamma, and c-myc in activated human peripheral blood T cells. Tacrolimus 0-5 interferon gamma Homo sapiens 247-256 32749395-5 2020 Furthermore, T cell infiltration, and secretion of IL-2 and IFN-gamma were dramatically reduced in the GM-FK506 group. Tacrolimus 106-111 interferon gamma Homo sapiens 60-69 32180132-7 2020 IFN-gamma potently enhanced TNFA, IL12, HLADRA1 and LRRK2 expression, which was suppressed by FK506, a calcineurin-specific inhibitor, but further enhanced by LRRK2-specific kinase inhibitor (GSK2578215A). Tacrolimus 94-99 interferon gamma Homo sapiens 0-9 32817992-4 2020 Results Tacrolimus significantly increased the expression of LIF, IL-10, and IL-17 and decreased the expression of IL-4, IFN-gamma, and the IFN-gamma/IL-10 ratio in RIF patients. Tacrolimus 8-18 interferon gamma Homo sapiens 121-130 32817992-4 2020 Results Tacrolimus significantly increased the expression of LIF, IL-10, and IL-17 and decreased the expression of IL-4, IFN-gamma, and the IFN-gamma/IL-10 ratio in RIF patients. Tacrolimus 8-18 interferon gamma Homo sapiens 140-149 28673995-5 2017 Accordingly, a histone deacetylase inhibitor (HDACi) could reduce IPS in the state where IFN-gamma expression was suppressed by FK506. Tacrolimus 128-133 interferon gamma Homo sapiens 89-98 32499781-7 2020 Cyclosporine A, tacrolimus and steroids dose-dependently inhibited IFN-gamma secretion, and reactivity was further reduced when calcineurin inhibitors were combined with steroids. Tacrolimus 16-26 interferon gamma Homo sapiens 67-76 30293884-9 2019 Interferon (IFN)-gamma concentrations in peripheral blood also diminished significantly with tacrolimus (P<0.01). Tacrolimus 93-103 interferon gamma Homo sapiens 0-22 30931336-14 2019 Furthermore, they could demonstrate that treatment with the immunosuppressive drug tacrolimus resulted in decreased CMV-specific IFN-gamma and of IL-21 production. Tacrolimus 83-93 interferon gamma Homo sapiens 129-138 30472069-6 2019 We determined that tacrolimus profoundly suppressed CD4 and CD8 T cell proliferation and significantly suppressed Th1 and Th17 responses, as demonstrated by a reduced frequency of IFN-gamma, IL-2, and IL-17 producing CD4 T cells and reduced frequencies of IFN-gamma and IL-2 producing CD8 T cells. Tacrolimus 19-29 interferon gamma Homo sapiens 180-189 30472069-6 2019 We determined that tacrolimus profoundly suppressed CD4 and CD8 T cell proliferation and significantly suppressed Th1 and Th17 responses, as demonstrated by a reduced frequency of IFN-gamma, IL-2, and IL-17 producing CD4 T cells and reduced frequencies of IFN-gamma and IL-2 producing CD8 T cells. Tacrolimus 19-29 interferon gamma Homo sapiens 256-265 30472069-7 2019 Tacrolimus also inhibits pathogenic Th17 cells coproducing IL-17 and IFN-gamma. Tacrolimus 0-10 interferon gamma Homo sapiens 69-78 23274966-9 2013 In a comparison of the relative potency of each drug at different dosing ranges, tacrolimus had the strongest Th1 inhibitory effect (median inhibition of interferon-gamma at 97.5%; P=0.004-0.008) followed by sirolimus (median inhibition at 82.4%). Tacrolimus 81-91 interferon gamma Homo sapiens 154-170 25925687-10 2015 Analyses showed that >16 HLA-DQ epitope mismatches and pretransplant, peripheral blood, donor-reactive IFN-gamma ELISPOT assay results correlated with development of DSAs and/or AR on tacrolimus withdrawal. Tacrolimus 187-197 interferon gamma Homo sapiens 106-115 25905982-5 2015 RESULTS: Tacrolimus significantly and SRL modestly inhibited interferon (IFN)-gamma (Th1) and IL-17 (Th17)-producing cells. Tacrolimus 9-19 interferon gamma Homo sapiens 61-83 28747916-4 2017 Here, we determined the effect of tacrolimus and MPA on DNA methylation of the gene promoter region of interferon gamma (IFNgamma), a pro-inflammatory cytokine. Tacrolimus 34-44 interferon gamma Homo sapiens 103-130 28747916-12 2017 IFNgamma protein production was suppressed by tacrolimus. Tacrolimus 46-56 interferon gamma Homo sapiens 0-8 24342979-7 2014 RESULTS: Cyclosporine A and tacrolimus significantly reduced IFNgamma production in a dose-dependent manner (53%-83%), but showed minimal effect on degranulation (20%). Tacrolimus 28-38 interferon gamma Homo sapiens 61-69 21195813-10 2011 We found that tacrolimus reduced levels of the IFN-gamma, IL-2, IL-10, and IL-13 cytokines and induced the proliferation of tolerogenic plasmacytoid dendritic cells after treatment. Tacrolimus 14-24 interferon gamma Homo sapiens 47-56 22008665-9 2012 We found the recipients with higher IL-18 and IFN-gamma serum levels had lower tacrolimus concentration/dose (C/D) ratios (P<0.05). Tacrolimus 79-89 interferon gamma Homo sapiens 46-55 19880819-13 2010 Tacrolimus AER was superior to TAC MED at preventing AE IFN-gamma, IL-10, IL-13, monocyte chemoattractant protein-1 chemokine (C-C motif) ligand 5 (RANTES) and TNF-alpha up-regulation. Tacrolimus 0-10 interferon gamma Homo sapiens 56-65 21227887-0 2011 Effects of tacrolimus on IFN-gamma signaling in keratinocytes: possible mechanisms by which tacrolimus affects IFN-gamma-dependent skin inflammation. Tacrolimus 11-21 interferon gamma Homo sapiens 25-34 21227887-0 2011 Effects of tacrolimus on IFN-gamma signaling in keratinocytes: possible mechanisms by which tacrolimus affects IFN-gamma-dependent skin inflammation. Tacrolimus 92-102 interferon gamma Homo sapiens 25-34 21227887-0 2011 Effects of tacrolimus on IFN-gamma signaling in keratinocytes: possible mechanisms by which tacrolimus affects IFN-gamma-dependent skin inflammation. Tacrolimus 92-102 interferon gamma Homo sapiens 111-120 21227887-3 2011 This study explored the mechanism of tacrolimus-modulated IFN-gamma signal transduction in HaCaT keratinocytes and the effects of tacrolimus on IFN-gamma-associated cytokine production in HaCaT cells. Tacrolimus 37-47 interferon gamma Homo sapiens 58-67 21227887-3 2011 This study explored the mechanism of tacrolimus-modulated IFN-gamma signal transduction in HaCaT keratinocytes and the effects of tacrolimus on IFN-gamma-associated cytokine production in HaCaT cells. Tacrolimus 130-140 interferon gamma Homo sapiens 144-153 21227887-4 2011 Tacrolimus down-regulated the recombinant human IFN-gamma (rhIFN-gamma)-induced expression of IFN-gamma receptor alpha (IFN-gammaRalpha). Tacrolimus 0-10 interferon gamma Homo sapiens 48-57 21227887-4 2011 Tacrolimus down-regulated the recombinant human IFN-gamma (rhIFN-gamma)-induced expression of IFN-gamma receptor alpha (IFN-gammaRalpha). Tacrolimus 0-10 interferon gamma Homo sapiens 61-70 21227887-5 2011 The IFN-gamma induced expression of phosphorylated Janus kinase 2 (pJAK2) and phosphorylated signal transducer and activator of transcription-1 (pSTAT-1) was also inhibited by tacrolimus. Tacrolimus 176-186 interferon gamma Homo sapiens 4-13 21227887-6 2011 Tacrolimus up-regulated the IFN-gamma-induced expression of suppressor of cytokine signaling-1 (SOCS-1). Tacrolimus 0-10 interferon gamma Homo sapiens 28-37 21227887-7 2011 Tacrolimus was also demonstrated to down-regulate IFN-gamma-induced the secretion of chemotactic factor CXCL-8 and the expression of intercellular adhesion molecule-1 and human leucocyte antigen HLA-DR. Tacrolimus 0-10 interferon gamma Homo sapiens 50-59 21227887-8 2011 The findings in this work indicate that the direct effects of tacrolimus on IFN-gamma signaling in keratinocytes may contribute to its therapeutic efficacy as a topical ointment in the treatment of IFN-gamma-dependent skin inflammation. Tacrolimus 62-72 interferon gamma Homo sapiens 76-85 21227887-8 2011 The findings in this work indicate that the direct effects of tacrolimus on IFN-gamma signaling in keratinocytes may contribute to its therapeutic efficacy as a topical ointment in the treatment of IFN-gamma-dependent skin inflammation. Tacrolimus 62-72 interferon gamma Homo sapiens 198-207 18262659-3 2008 The culture study showed reduced IL-12, IL-17, IFN-gamma, GM-CSF, TNF-alpha and MIP-1beta, and elevated IL-10 in the PBMC from patients who received tacrolimus, which suggests inhibition of T cells and macrophages, and enhancement of type 1 regulatory T cells. Tacrolimus 149-159 interferon gamma Homo sapiens 47-56 20159692-6 2010 CONCLUSION: FK506 effectively inhibits the secretion of proinflammatory cytokines including IL-6, IFN-gamma and TNF-alpha and also the secretion of IL-2, IL-12, IL-17, GM-CSF and G-CSF. Tacrolimus 12-17 interferon gamma Homo sapiens 98-107 20159692-4 2010 RESULTS: Compared with the control group, high-concentration FK506 (20 ng/ml) significantly inhibited the secretions of IL-2, IL-6, IL-12, IL-17, IFN-gamma, TNF-alpha, GM-CSF and G-CSF. Tacrolimus 61-66 interferon gamma Homo sapiens 146-155 15996247-8 2005 Pre-transplant donor-directed IFN-gamma ELISPOT assessment of anti-donor cellular immunity may function as a "cellular crossmatch" and independently correlates with renal allograft function in African Americans receiving tacrolimus- and sirolimus-based immunosuppression. Tacrolimus 221-231 interferon gamma Homo sapiens 30-39 17594193-2 2007 Tacrolimus inhibits the activation of an essential transcription factor for the transcription of cytokine genes in T cells leading to a decreased production of cytokines such as IL-2 and IFN-gamma. Tacrolimus 0-10 interferon gamma Homo sapiens 187-196 17051976-9 2006 IFN-gamma production is inhibited by IL-4, IL-10, TGFbeta, glucocorticoids, cyclosporin A and FK506. Tacrolimus 94-99 interferon gamma Homo sapiens 0-9 16641133-3 2006 Here, we show that calcineurin antagonists such as cyclosporin A (CsA) or tacrolimus can markedly enhance the production of interferon-gamma (IFN-gamma) by human T cells. Tacrolimus 74-84 interferon gamma Homo sapiens 124-140 16641133-3 2006 Here, we show that calcineurin antagonists such as cyclosporin A (CsA) or tacrolimus can markedly enhance the production of interferon-gamma (IFN-gamma) by human T cells. Tacrolimus 74-84 interferon gamma Homo sapiens 142-151 15115509-3 2004 Topical tacrolimus may inhibit local activation of T lymphocytes through altered expression of cytokines such as interleukin-1, -4 and -5, tumour necrosis factor-alpha and interferon-gamma. Tacrolimus 8-18 interferon gamma Homo sapiens 172-188 14767008-5 2004 Although interleukin (IL)-12 production of DC was impaired, they did not promote Th2 development as T cells activated by tacrolimus-treated DC produced less interferon (IFN)-gamma, IL-4 and IL-10. Tacrolimus 121-131 interferon gamma Homo sapiens 157-179 11563819-6 2001 Tacrolimus treatment added with donor specific BMT down-regulated IL-12 and IFN-gamma transcript, resulted in a significant prolongation of intestinal allograft survival. Tacrolimus 0-10 interferon gamma Homo sapiens 76-85 12767900-1 2003 We previously reported synergistic induction of apoptosis by IFN-gamma plus either cyclosporin A (CsA) or tacrolimus (FK506) in gastric carcinoma cells. Tacrolimus 118-123 interferon gamma Homo sapiens 61-70 12767900-8 2003 Activation of NF-kappa B occurred in response to IFN-gamma, and which was markedly inhibited by either CsA or FK506. Tacrolimus 110-115 interferon gamma Homo sapiens 49-58 11477316-0 2001 Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Tacrolimus 37-47 interferon gamma Homo sapiens 100-116 11477316-1 2001 The authors have determined the frequency of intracellular interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) synthesis by T-cell subsets in whole blood (WB) and isolated lymphocytes in 16 transplant recipients treated with tacrolimus and 10 control patients who were not transplant recipients. Tacrolimus 227-237 interferon gamma Homo sapiens 84-100 11477316-1 2001 The authors have determined the frequency of intracellular interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) synthesis by T-cell subsets in whole blood (WB) and isolated lymphocytes in 16 transplant recipients treated with tacrolimus and 10 control patients who were not transplant recipients. Tacrolimus 227-237 interferon gamma Homo sapiens 102-111 11407316-6 2001 In a comparative study with steroids (alclometasone dipropionate and betamethason valerate) in anti-CD3/CD2 system, tacrolimus and both steroids inhibited Th1 cytokines (IL-2, IFN-gamma), Th2 cytokines (IL-4, IL-5) and IL-3, GM-CSF (produced by both Th1 and Th2). Tacrolimus 116-126 interferon gamma Homo sapiens 176-185 10789681-2 2000 In contrast, the production of IFN-gamma was highly sensitive to FK506 (IC50 = 0.01 nM) and could be completely blocked by FK506. Tacrolimus 65-70 interferon gamma Homo sapiens 31-40 11137126-7 2000 Daily intramuscular treatment of GB piglets with 1mg/kg of FK506 from birth for 4 weeks resulted in lowered (P<0.05) in vitro secretion of interferon-gamma and interleukin-8. Tacrolimus 59-64 interferon gamma Homo sapiens 142-158 11137126-9 2000 The depletions of mononuclear cells and low levels of interferon-gamma and interleukin-8 in piglets treated with FK506 were accompanied by lower proportion of CD3+, CD2+CD4+ and CD2+CD8+ T-cell phenotypes in peripheral blood but not in thymus and mesenteric lymph nodes. Tacrolimus 113-118 interferon gamma Homo sapiens 54-70 11131636-2 2000 The apoptosis inducing effect of interferon-gamma and its modulation by cyclosporin-A or tacrolimus (FK-506) were investigated in in vitro and ex vivo experiments. Tacrolimus 89-99 interferon gamma Homo sapiens 33-49 11131636-2 2000 The apoptosis inducing effect of interferon-gamma and its modulation by cyclosporin-A or tacrolimus (FK-506) were investigated in in vitro and ex vivo experiments. Tacrolimus 101-107 interferon gamma Homo sapiens 33-49 10789681-2 2000 In contrast, the production of IFN-gamma was highly sensitive to FK506 (IC50 = 0.01 nM) and could be completely blocked by FK506. Tacrolimus 123-128 interferon gamma Homo sapiens 31-40 7519528-11 1994 RESULTS: After 4-6 weeks of FK-506 therapy, human IgG, all thyroid antibodies and IFN-gamma were suppressed, while the levels remained elevated in the control group. Tacrolimus 28-34 interferon gamma Homo sapiens 82-91 10205001-7 1999 Moreover, incubation of activated macrophages with CsA and FK506 contributed to maintain higher levels of Bcl-2 than in LPS/IFN-gamma treated cells. Tacrolimus 59-64 interferon gamma Homo sapiens 124-133 9190906-2 1997 Furthermore we show that IL-10 production by human T cell lines, such as IFN-gamma and IL-2, is inhibited by the immunosuppressive drugs cyclosporin A and FK506. Tacrolimus 155-160 interferon gamma Homo sapiens 73-82 8846199-6 1995 FK506 strongly suppressed the production of IL-2 (IC50 = 0.01 microM) and GM-CSF (IC50 = 0.03 microM), but was inactive (< 30% inhibition at 1 microM) against IL-5 and IFN-gamma. Tacrolimus 0-5 interferon gamma Homo sapiens 171-180 10515221-11 1999 In conclusion, our study clearly demonstrated that studied ex vivo, FK506 and CsA decrease the frequencies of cells expressing IL-2, IL-4 and IL-2/IFN-gamma in vivo but do not affect those expressing IFN-gamma. Tacrolimus 68-73 interferon gamma Homo sapiens 147-156 9510155-8 1998 FK506 also reduced CD3/CD28-induced production of IL-3, IL-4, IL-10, TNF-alpha, and IL-6 but augmented that of GM-CSF, IL-5, IFN-gamma, and IL-13. Tacrolimus 0-5 interferon gamma Homo sapiens 125-134 7507316-6 1993 For instance, CsA and FK 506 inhibit the transcription of IL-3, IL-4, IFN gamma, TNF alpha or GM-CSF by activated T cells, and rapamycin has been shown to block the response to various growth factors such as IL-3, IL-4 or IL-6. Tacrolimus 22-28 interferon gamma Homo sapiens 70-79 7526029-2 1994 Primary cultured thyroid cells were incubated for three days with IFN gamma (10 to 800 U/ml) or PHA (1 to 50 micrograms/ml) in the presence of FK506. Tacrolimus 143-148 interferon gamma Homo sapiens 66-75 7509103-1 1993 We investigated the effects of FK506, a novel immunosuppressive agent, on the phytohemagglutinin (PHA) or interferon-gamma (IFN-gamma)-induced expression of HLA-DR antigen, accessory cell function and proliferation of primary cultured human thyroid cells. Tacrolimus 31-36 interferon gamma Homo sapiens 106-133 7683267-8 1993 Immunocytochemistry demonstrated that FK506 reduced the expression of interferon-gamma induced major histocompatibility complex (MHC) class I on the proximal tubular cells, but had no effect on the expression of the MHC class II antigens or the intercellular adhesion molecule (ICAM-1) on the cultured cells. Tacrolimus 38-43 interferon gamma Homo sapiens 70-86 1380951-3 1992 While 1 microgram/ml CSA and 0.1 microgram/ml FK 506 completely suppressed PHA-stimulated accumulation of mRNA for IL2, IL4, IL9, GM-CSF, TNF-alpha and IFN-gamma in PBMC, flu, keto and TGF-beta failed to inhibit any (except TNF-alpha blocked by TGF-beta). Tacrolimus 46-52 interferon gamma Homo sapiens 152-161 7680613-2 1993 SEB-activated lamina propria T cells produced interleukin-2 and interferon-gamma and T cell activation was accompanied by tissue damage, which was inhibited by FK506. Tacrolimus 160-165 interferon gamma Homo sapiens 64-80 1717376-1 1991 Cyclosporin (CsA) and FK-506 are structurally distinct fungal metabolites, which exert powerful inhibitory effects on CD4+ T (helper) cell activation and on the secretion of interleukin-2 (IL-2) and other cytokines, including various cell growth factors and interferon-gamma. Tacrolimus 22-28 interferon gamma Homo sapiens 258-274 1371491-8 1992 When the cells were stimulated by phorbol ester (phorbol 12-myristate 13-acetate, PMA) plus calcium ionophore (ionomycin), FK506 and CsA inhibited, in a dose-dependent manner, the production of IL-2, IL-4, IL-5, IFN-gamma and TNF-alpha. Tacrolimus 123-128 interferon gamma Homo sapiens 212-221 1371491-10 1992 Further stimulation by addition of anti-CD28 mAb to the cultures resulted in an augmented IL-2 and IFN-gamma production which was resistant to both FK506 and CsA. Tacrolimus 148-153 interferon gamma Homo sapiens 99-108 34668283-5 2021 With increasing concentrations of tacrolimus, there was a trend to reduction in the release of IL-2 (p = 0.0137), and IFN-gamma (p = 0.0147) in response to peptide stimulation. Tacrolimus 34-44 interferon gamma Homo sapiens 118-127 35126303-7 2021 The proportion of CD19+BAFFR+, CD19+IFN-gamma+, and CD19+IL-10+ subsets decreased significantly after TAC therapy (p = 0.015, 0.018, and 0.042, respectively). Tacrolimus 102-105 interferon gamma Homo sapiens 36-45 35126303-9 2021 Conclusion: Possibly through increasing regulatory B and suppressing BAFFR+ B and interferon (IFN)-gamma+ B subsets, TAC could decrease relapse. Tacrolimus 117-120 interferon gamma Homo sapiens 82-104 34619854-13 2021 The level of IFN-gamma in CD8+T cells group after applying tacrolimus was significantly lower than that in the blank control group (P<0.05). Tacrolimus 59-69 interferon gamma Homo sapiens 13-22